Drug Profile
Interferon alfacon-1
Alternative Names: Advaferon; CIFN; IFN-consensus; Infarex; Infergen; Interferon consensus; Interferon-alpha con1; Interferon-alpha consensus; rConINF; Recombinant consensus interferon; Recombinant methionyl interferon consensus; YM 643Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Amgen
- Developer Astellas Pharma; Three Rivers Pharmaceuticals
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
- Discontinued Cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Severe acute respiratory syndrome